PROCEPT BIOROBOTICS CORP (PRCT) Stock Price & Overview

NASDAQ:PRCT • US74276L1052

Current stock price

25.12 USD
-0.24 (-0.95%)
At close:
24.86 USD
-0.26 (-1.04%)
After Hours:

The current stock price of PRCT is 25.12 USD. Today PRCT is down by -0.95%. In the past month the price decreased by -0.91%. In the past year, price decreased by -50.97%.

PRCT Key Statistics

52-Week Range19.35 - 66.85
Current PRCT stock price positioned within its 52-week range.
1-Month Range22.77 - 28.68
Current PRCT stock price positioned within its 1-month range.
Market Cap
1.417B
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.71
Dividend Yield
N/A

PRCT Stock Performance

Today
-0.95%
1 Week
+0.20%
1 Month
-0.91%
3 Months
-18.34%
Longer-term
6 Months -30.16%
1 Year -50.97%
2 Years -52.59%
3 Years -17.34%
5 Years N/A
10 Years N/A

PRCT Stock Chart

PROCEPT BIOROBOTICS CORP / PRCT Daily stock chart

PRCT Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to PRCT. When comparing the yearly performance of all stocks, PRCT is a bad performer in the overall market: 91.32% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PRCT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to PRCT. The financial health of PRCT is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRCT Earnings

On February 25, 2026 PRCT reported an EPS of -0.53 and a revenue of 76.38M. The company missed EPS expectations (-60.27% surprise) and missed revenue expectations (-20.45% surprise).

Next Earnings DateApr 30, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.53
Revenue Reported76.383M
EPS Surprise -60.27%
Revenue Surprise -20.45%

PRCT Forecast & Estimates

21 analysts have analysed PRCT and the average price target is 33.58 USD. This implies a price increase of 33.66% is expected in the next year compared to the current price of 25.12.

For the next year, analysts expect an EPS growth of 15.53% and a revenue growth 21.53% for PRCT


Analysts
Analysts78.1
Price Target33.58 (33.68%)
EPS Next Y15.53%
Revenue Next Year21.53%

PRCT Groups

Sector & Classification

PRCT Financial Highlights

Over the last trailing twelve months PRCT reported a non-GAAP Earnings per Share(EPS) of -1.71. The EPS increased by 2.84% compared to the year before.


Income Statements
Revenue(TTM)308.05M
Net Income(TTM)-95.57M
Industry RankSector Rank
PM (TTM) N/A
ROA -18.81%
ROE -26.12%
Debt/Equity 0.14
Chartmill High Growth Momentum
EPS Q2Q%-51.43%
Sales Q2Q%11.94%
EPS 1Y (TTM)2.84%
Revenue 1Y (TTM)37.22%

PRCT Ownership

Ownership
Inst Owners103.56%
Shares56.39M
Float54.51M
Ins Owners4.35%
Short Float %11.93%
Short Ratio3.75

About PRCT

Company Profile

PRCT logo image PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 888 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.

Company Info

IPO: 2021-09-15

PROCEPT BIOROBOTICS CORP

150 Baytech Drive

San Jose CALIFORNIA US

CEO: Reza Zadno

Employees: 888

PRCT Company Website

PRCT Investor Relations

Phone: 18887167274

PROCEPT BIOROBOTICS CORP / PRCT FAQ

What does PRCT do?

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 888 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.


What is the current price of PRCT stock?

The current stock price of PRCT is 25.12 USD. The price decreased by -0.95% in the last trading session.


Does PROCEPT BIOROBOTICS CORP pay dividends?

PRCT does not pay a dividend.


What is the ChartMill rating of PROCEPT BIOROBOTICS CORP stock?

PRCT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Is PROCEPT BIOROBOTICS CORP (PRCT) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRCT.


What is PROCEPT BIOROBOTICS CORP worth?

PROCEPT BIOROBOTICS CORP (PRCT) has a market capitalization of 1.42B USD. This makes PRCT a Small Cap stock.


Who owns PROCEPT BIOROBOTICS CORP?

You can find the ownership structure of PROCEPT BIOROBOTICS CORP (PRCT) on the Ownership tab.